Clinical data | |
---|---|
Trade names | Loargys |
Other names | AEB-1102 |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C1554H2492N416O463S6 |
Molar mass | 34603.84 g·mol−1 |
Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia. [1] [2]
The most common side effects include allergic reactions. [1]
Pegzilarginase was approved for medical use in the European Union in December 2023. [2]
Pegzilarginase is indicated for the treatment of arginase 1 deficiency, also known as hyperargininemia. [1] [2]
In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia. [1] The applicant for this medicinal product is Immedica Pharma AB. [1] Pegzilarginase was approved for medical use in the European Union in December 2023. [2]
Pegzilarginase is the international nonproprietary name. [3]
Pegzilarginase is sold under the brand name Loargys. [1]
Clinical data | |
---|---|
Trade names | Loargys |
Other names | AEB-1102 |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C1554H2492N416O463S6 |
Molar mass | 34603.84 g·mol−1 |
Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia. [1] [2]
The most common side effects include allergic reactions. [1]
Pegzilarginase was approved for medical use in the European Union in December 2023. [2]
Pegzilarginase is indicated for the treatment of arginase 1 deficiency, also known as hyperargininemia. [1] [2]
In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia. [1] The applicant for this medicinal product is Immedica Pharma AB. [1] Pegzilarginase was approved for medical use in the European Union in December 2023. [2]
Pegzilarginase is the international nonproprietary name. [3]
Pegzilarginase is sold under the brand name Loargys. [1]